Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Midazolam autoinjector - Crossject

Next Previous
Drug Profile

Midazolam autoinjector - Crossject

Alternative Names: ZENEO® Midazolam - Crossject; ZEPIZURE®

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crossject
  • Class 3-ring heterocyclic compounds; Antiepileptic drugs; Benzodiazepines; Chlorinated hydrocarbons; Fluorobenzenes; Hypnosedatives; Imidazoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Status epilepticus

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Status-epilepticus(In volunteers) in South Africa (IM, Injection)
  • 07 May 2025 Crossject expects to receive Emergency Use Authorization (EUA) for Midazolam autoinjector for Status epilepticus, in the US in June 2025
  • 07 May 2025 CROSSJECT plans to file MAA for Midazolam autoinjector for Status epilepticus in EU

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top